Nuvectis Pharma Inc NVCT

$19.39 -0.45 (-2.27%)

Valuation

Market cap
666,803,000
Revenue TTM
$0
Net income TTM
$-26,440,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
301,600
Avg volume
208,758
Day's range
$19.02 – $20.18
Shares out
34,389,000
Stochastic %K
24%
Beta
-0.21
Analysts
Moderate Buy
Price target
$35.50

Price

Company profile

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry P...

Show more

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Phone
201 614 3150
Website
https://www.nuvectis.com
Address
1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, United States

Latest news

Stocktwits

GTA_Terminal Nov 9, 11:16 AM
Dark pool check on $NVCT: what traded off the exchanges in the latest session. That came on a day the stock jumped hard, so the question is whether big holders were chasing it or selling into it. Read the full article for the full details: https://globaltradersacademy.com/articles/dark-pool-activity-what-big-money-did-in-nuvectis-pharma-nvct-off-the-exchanges?utm_source=stocktwits&utm_medium=social
0 replies
UNLV Nov 6, 6:33 PM
$NVCT Once promised 2026 data readouts for NXP900 1b mono and resistance combo therapies now 1H 2027. Insiders not selling and my PT. Deprioritizing assets understandable for asset rich small biotech. NXP100 will be muti billion blockbuster by itself for this 600M market cap. GLSI another small biotech stock I'm very deep
0 replies
shoc24 Nov 4, 3:27 PM
$NVCT reported earnings before the open today. GAAP EPS missed estimates: -$1.02 vs. -$0.24 expected, according to Stock Meadow.
0 replies
EarningsInsider Nov 4, 2:02 PM
https://www.marketbeat.com/earnings/reports/2026-11-4-nuvectis-pharma-inc-stock/ $NVCT Nuvectis Pharma Earnings Transcript
0 replies
StocktwitsEarnings Nov 4, 1:09 PM
$NVCT Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.20 up 54.55% YoY • Nuvectis Pharma expects research and development expenses to increase substantially in the near term and beyond, and general and administrative expenses to increase in the future as headcount expands to support development and corporate activities.
0 replies
focafoca99 Nov 4, 12:22 PM
$NVCT reports its Q3 2026 financial results via a press release.
0 replies
WallStWireAds Nov 4, 12:09 PM
$NVCT https://www.globenewswire.com/news-release/2026/11/04/3395165/0/en/nuvectis-pharma-reports-third-quarter-2026-financial-results-and-b
0 replies
WallStWireAds Nov 4, 12:02 PM
$NVCT Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights >> https://caplynx.io/4yZ5pK0
0 replies